Conditions: Colorectal Neoplasms
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 1
Healthy volunteers: no

Brief summary:
The objective of this Phase II study is to assess the efficacy and safety of nintedanib alone or in combination with capecitabine for patients with refractory metastatic colorectal cancer (mCRC) after failure of at least 2 lines of standard treatment

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: Nintedanib intervention 2: Capecitabine
Intervention descriptions: intervention 1: None intervention 2: None

Protocol document: